FDA Warning Letters Citing GLP-1 Drugs, 2024 to 2026

Every FDA warning letter posted on fda.gov, dated January 2024 or later, that cites a GLP-1 drug (semaglutide, tirzepatide, retatrutide or liraglutide, under any brand or code name) and went to a telehealth company, clinic, compounding pharmacy, outsourcing facility, online seller or drugmaker: 153 letters dated Feb 7, 2024 to Sep 24, 2026. Each row gives the letter date, the recipient, what FDA cited (products, claims and sections of the Food, Drug, and Cosmetic Act), a status note on close-out letters, and the fda.gov URL. Every letter was opened on fda.gov on Oct 27, 2026. Left out: letters to bulk ingredient makers, letters about a drugmaker's safety reporting, untitled letters and cease-and-desist letters. One CSV (8 columns, UTF-8, ISO 8601 dates) and a README data dictionary. Updated when Wellchosen Health rechecks a source or fixes an error; there is no fixed schedule. Cite as: Wellchosen Health (2026). FDA Warning Letters Citing GLP-1 Drugs, 2024 to 2026 [Data set]. https://wellchosenhealth.com/glp-1/fda-warning-letters/